Plain-English translation of NCT04131036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →This study is looking at how two different ways of treating severe hemophilia A — one using intravenous factor VIII and one using emicizumab — affect your joints and bones over time. Researchers will use ultrasound scans and bone density measurements to track whether one treatment protects your joints better than the other. This matters because hemophilia can damage joints over time, and doctors want to understand which approach works best.
People with severe hemophilia A have two main prophylaxis (preventive treatment) options, but it's unclear whether one is better for protecting joints and bones long-term. This study will help doctors understand the real-world impacts of each treatment on bone and joint health.
You'll come in for a baseline visit and then return once a year for 3 years. At each visit, you'll have an ultrasound scan of your joints, a bone density scan, and may have blood drawn for research. Between visits, you'll answer brief phone surveys every 3 months about any bleeding and how you're doing. The whole study lasts 3 years, and you'll stay on whichever hemophilia treatment you're already using.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States